• English

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    Maryland Medicaid Pharmacy

    ​Preferred Drug List

    Pharmacy & Therapeutics Committee Meeting

    Public Meeting​​

    (A portion of the meeting may be closed to the public)
    Thursday November 4, 2021
    9:00 a.m. - 1:00 p.m.


    *​Please be advised that the November 4, 2021 Pharmacy and Therapeutics (P&T) Committee Public Meeting will be conducted virtually as a Webinar.  In order to attend​​ the meeting, you must register for the webinar using the following attendance​ registration linkAfter registering, you will receive a confirmation email containing information about joining the webinar.      



    • ​​Registration of Public Testimony Begins: September 16, 2021

    • Registration for Public Testimony EndsOctober 21, 2021


    Registration for Public Testimony

    • Prior registration is required. Registration outside the dates listed above will not be accepted. To register, click on the testimony registration link.

    • The registration form is interactive and all fields must be completed. Once submitted, the registration request is sent directly to the Department and confirmation of registration will be communicated electronically within 2 business days.

    • Each company, pharmaceutical manufacturer, organization, group or consumer selected to speak will be given one (1) time slot of five (5) minute for their presentation(s).

    • ​​Multiple speakers representing a company, pharmaceutical manufacturers, organizations, groups or consumers may register to speak; however the total time shall not exceed five (5) minutes.

    • ​​Please click the following link for current therapeutic classes and single drugs under review: November 2021 Meeting

    • Testimony must be limited to only those drugs contained in the therapeutic classes under review or the single drug review.


    Guidelines for Public Testimony

    • Public testimony at the P&T Committee meeting is limited to fifteen (15) presentations: twelve (12) speakers from the pharmaceutical industry and three (3) representing consumer interests.

    • If the full allotment for either group does not pre-register to speak, representatives from the other group will be selected in their place.

    • In the event more speakers have registered than there are spaces available, a lottery will be held to select  companies and consumers at random on the day after the deadline. The lottery involves a disinterested party drawing the names in the presence of two (2) witnesses.

    • All registrants will be notified 3 business days after the drawing, whether or not they have been selected to speak. 

    • Those selected to speak will be advised in the numerical order they will present at the P&T Committee meeting. After being selected, if you have a change in your choice of person to speak, please send an e-mail as soon as possible to:  mdh.marylandpdlquestions@maryland.gov.

    ​Selected Speakers’ Written Copy of Public Testimony (Mandatory)

    • MDH requires a written copy of the selected speaker’s public testimony be submitted via email to mdh.marylandpdlquestions@maryland.gov no later than five (5) business days prior to the meeting.

    • ​The written copy of public testimony should contain information that will be presented during the speaker’s public testimony.  

    ​Submission of Written Materials to the P&T Committee (Optional)

    • Stakeholders, including, pharmaceutical manufacturers, organizations, groups or consumers, have the opportunity to present comments to the P&T Committee through written material relating to only the therapeutic class and single drug (if, applicable) under review.

    • ​The written Material (​view Sample) must be:​​
      1. ​​Compatible with MS-Word or Adobe® Acrobat®
      2. Limited to no more than one standard page,​​ front and back with 'bulleted' points and include all drugs on which you want to provide information.
    • The written materials that are not  submitted in the above mentioned format will be returned to the  speaker with a request to re-submit in the format required

    • Submitted via email to: mdh.marylandpdlquestions@maryland.gov no later than five (5) business days prior to the meeting.

    • ​MDH will forward timely written materials and comments from Stakeholders to the members of the P&T Committee.

    ​Day of the P&T Committee Meeting

    • ​The meeting will start at approximately 9:00 a.m.  The Committee Chair will call on speakers in the order that their names were drawn in the speaker lottery.​

    • The time available for presentation(s) is up to five (5) minutes. Thirty (30) seconds before the end of the presentation, speakers will receive warning that time has almost expired.

    • Registered speakers may share their time slots; however, there is only one time slot given to a company, pharmaceutical manufacturer, or organization.

    • In the event a selected speaker fails to appear at the meeting, his or her time will be forfeited, and that slot will remain unfilled.

    • ​Please note that neither audio-visual equipment nor product demonstrations will be permitted.

    • ​​There will be no question and answer period.​